Thrombin [bovine origin] 5000 IU, 20000 IU; per vial; pwd for topical use after reconstitution; preservative-free. Thrombin-JMI requires no intermediate physiological agent for its action.

Summary: Ximelagatran is the first orally active direct thrombin inhibitor to be tested in Phase III clinical trials. After oral administration, ximelagatran is rapidly converted to its active ...

Direct inhibition of thrombin may offer similar anticoagulant properties but also impact the underlying disease process. As we continue to gain experience and develop new DTIs, a new balance may ...

Antithrombin, a plasma protein, has been reported to control thrombin activity by directly binding to thrombin, as well as to have an anti-inflammatory effect. However, the actual molecular ...

Intravenous administration only. Used for the treatment of HIT (heparin induced thrombocytopenia). Monitored by aPTT - goal is 1.5 to 3.0 times above baseline. Renally cleared. Not easily reversed ...

Four years ago, protein drug developer Zymogenetics in Seattle began developing a recombinant version of the blood-clotting protein thrombin. On 17 January, it received US marketing approval for ...

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...